Am J Transplant, Volume 20, Suppl 3 Archives - Page 101 of 223 - ATC Abstracts

2020 American Transplant Congress
Causes of Kidney Allograft Loss (GL) in the Current Era of Donor-Specific Alloantibody (DSA) Testing
M. Merzkani¹, X. Benavides¹, M. D'Costa¹, B. Smith¹, W. Park¹, A. Rule¹, H. Chakkera², K. Reddy², M. Alexander¹, H. Amer¹, M. El Ters¹, C. Schinstock¹, R. Heilman², A. Bentall¹, M. Stegall¹
¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
*Purpose: The goal of this study was to examine the causes and risk factors (RF) for renal GL in the era since the widespread adoption…
2020 American Transplant Congress
A Proof-of-Principle Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)
A. Chruscinski¹, S. Juvet¹, S. Moshkelgosha¹, E. Renner¹, L. Lilly¹, N. Selzner¹, C. Bredeson², O. Adeyi¹, S. Fischer¹, A. Demetris³, J. Zhang¹, M. Epstein¹, A. Clement², K. Khalili¹, Z. Galvin¹, A. Humar¹, T. Kim¹, K. Tinckham¹, T. Yi¹, G. Levy¹, H. Atkins²
¹Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³University of Pittsburgh, Pittsburgh, PA
*Purpose: Long-term survival of recipients of solid organ transplants is limited by chronic rejection, disease recurrence and immunosuppression-induced toxicity. Self-tolerance is established after autologous hematopoietic…
2020 American Transplant Congress
History of Coronary Artery Disease Predicts Inferior Survival in Liver Transplant Recipients of Advanced Age in a Large Multicenter U.S. Cohort
M. German¹, A. Hristov¹, A. Lee¹, F. Osman¹, A. Kwong², D. Devuni³, C. Wang⁴, J. Boike⁵, J. Jo⁵, L. VanWagner⁵, M. Serper⁶, R. Sharma⁷, E. Verna⁷, J. Shor³, A. Koteish⁸, G. Sehmbey⁹, A. Seetharam⁹, N. John², Y. Patel¹⁰, M. Kappus¹⁰, T. Couri¹¹, S. Paul¹¹, R. Salgia¹², Q. Nhu¹³, C. Frenette¹³, J. Lai⁴, A. Goel², E. Spengler¹
¹U of Wisconsin, Madison, WI, ²Stanford, Palo Alto, CA, ³U of Massachusetts, Worcester, MA, ⁴U of California, San Francisco, CA, ⁵Northwestern, Chicago, IL, ⁶U of Pennsylvania, Philadelphia, PA, ⁷Columbia, New York, NY, ⁸Florida Hospital, Orlando, FL, ⁹U of Arizona, Phoenix, AZ, ¹⁰Duke, Durham, NC, ¹¹U of Chicago, Chicago, IL, ¹²Henry Ford Hospital, Detroit, MI, ¹³Scripps, San Diego, CA
*Purpose: Coronary artery disease (CAD) is common in patients of advanced age and does not preclude liver transplantation (LT) if adequately treated. We aimed to…
2020 American Transplant Congress
MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?
A. Santos¹, C. Chen¹, K. Alquadan², M. A. Leghrouz², X. Wen³
¹University of Florida, Gainesville, FL, ²Division of Nephrology, Hypertension, & Renal Transplantation, University of Florida, Gainesville, FL, ³Department of Pharmacy Practice, University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs) in categories of donor/recipient pre-transplant…
2020 American Transplant Congress
Quantifiable Loss of Insulin Secretory Granules in Delayed Endocrine Pancreas Graft Function in Comparison to Controls
C. B. Drachenberg¹, J. C. Papadimitriou¹, J. R. Scalea², A. Haririan³, R. Ugarte³, S. Niederhaus², J. Bromberg²
¹Pathology, University of Maryland, Baltimore, MD, ²Surgery, University of Maryland, Baltimore, MD, ³Medicine, University of Maryland, Baltimore, MD
*Purpose: Approximately 1/3 of pancreas transplant fail to gain glycemic control in the first days/weeks posttransplantation, requiring exogenous insulin administration. Delayed endocrine pancreas graft function…
2020 American Transplant Congress
Association of Kidney Allograft Fibrosis-Associated Proteins with Chronic Lung Allograft Dysfunction
S. Farkona¹, G. Berra², Z. Mohammed-Ali¹, P. Ly², L. Levy², B. Renaud-Picard², G. Zehong², T. Daigneault², S. Juvet², C. McEvoy¹, S. Clotet-Freixas¹, T. Martinu², A. Konvalinka¹
¹Nephrology, Toronto General Hospital Research Institute and Multi-Organ Transplant, University Health Network, Toronto, ON, Canada, ²Lung Transplantation, Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD) remains the leading cause of long-term mortality after lung transplant. Non invasive biomarkers that could assist in early diagnosis…
2020 American Transplant Congress
Next Generation Sequencing B Cell Receptor Reveals B Cell Clones Encoding HLA Antibody in Transplant Recipients
X. Zhang
HLA and Immunogenetcis Laboratory /CTC, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: The development of HLA donor specific antibodies (DSA) increases the risk of antibody mediated rejection and is an independent predictor of poor patient survival.…
2020 American Transplant Congress
Improving Evaluation and Follow-Up of Living Kidney Donors: Role of Radioisotopic Glomerular Filtration Rate and Renal Functional Reserve
V. Cantaluppi¹, G. Guglielmetti¹, U. M. Morosini¹, A. Nappo¹, G. Merlotti¹, A. Airoldi¹, M. Quaglia¹, C. Ronco²
¹Nephrology and Kidney Transplantation Unit, University of Piemonte Orientale (UPO), Novara, Italy, ²Nephrology, Dialysis and Kidney Transplantation Unit, University of Padova, Vicenza, Italy
*Purpose: After donation, living kidney donors (KD) develop an early and transient loss of kidney function (KF), defined as Acute Kidney Injury (AKI). Its recovery…
2020 American Transplant Congress
MELD is MELD is MELD? Geographic/ Center-Level Variation in Mortality for Patients with the Same MELD Score
T. Ishaque¹, A. B. Massie¹, A. B. Kernodle¹, S. Getsin¹, P. Chaing¹, J. G. Jacqueline Garonzik Wang¹, S. Gentry², D. Segev¹
¹Johns Hopkins University, Baltimore, MD, ²Department of Mathematics, United States Naval Academy, Annapolis, MD
*Purpose: Waitlist candidates living in areas with poor access to health care may have higher mortality risk compared to candidates with same MELD in other…
2020 American Transplant Congress
The Efficacy and Safety of Ischemia-Free Liver Transplantation (IFLT) in the Treatment of End-Stage Liver Disease in a Prospective, Randomized, Controlled Trial: A Report of the First 25 Cases
X. He, Z. Guo, Q. Zhao, C. Huang, W. Ju, D. Wang, M. Chen, L. Wu, Y. Ma, Y. Chen, A. Hu, X. Zhu
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
*Purpose: We’ve established a novel procedure called ischemia-free liver transplantation (IFLT). The results from the pilot study suggest that IFLT might prevent ischemia-reperfusion injury (IRI)…